Guillermo Garcia-Manero, MD, and Hagop Kantarjian, MD, discuss the phase 3 VERONA trial at SOHO 2025.
The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
